Cantor Fitzgerald Believes CRVS Won’t Stop HereBy Carrie Williams
Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) today and set a price target of $25. The company’s shares closed last Friday at $17.46, close to its 52-week high of $17.77.
“Off to a Good Start. Early data from the Phase I portion of the CPI-444 released at SITC in late-2016 demonstrated responses, either alone or in combination with atezolizumab.”
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 3.9% and a 46.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Cascadian Therapeutics, and Mirna Therapeutics Inc.
Currently, the analyst consensus on Corvus Pharmaceuticals Inc is Moderate Buy and the average price target is $25, representing a 43.2% upside.
In a report issued on March 10, Cowen & Co. also reiterated a Buy rating on the stock.
The company has a one year high of $17.77 and a one year low of $9.63. Currently, Corvus Pharmaceuticals Inc has an average volume of 28.28K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel immuno-oncology therapies designed to harness the immune system to attack cancer cells. Its products include CPE-444, an orally administered antagonist of the adenosine A2A receptor; Adenosine production inhibitor; Adenosine A2B antagonist; and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. The company was founded by Richard A. Miller, Leiv Lea, and Joseph J. Buggy in January 27, 2014 and is headquartered in Burlingame, CA.